Studies On The Experiments Of The Combination Of Interferon Alpha With Thymopeptide Alpha1 To Immune-tolerance Hepatitis B Virus Carriers

Hepatitis B (HB) is one of the most widely epidemic infectious diseases in the world, which has serious harmfulness and infectivity. The key of treatments on HB infection is to slow down or block the development of HB toward liver cirrhosis and hepatocellular carcinoma, clear HB virus (HBV) and reduce the injuries of liver. At present, most investigators view that the basic mechanism of HB infection chronicity is the immune non-response of the host to HBV (immune tolerance). Therefore the break of immune tolerance is the key step to cure the HBV patients, and then the host has normal immune response to HBV, which makes it possible to clear the viruses. In this study, interferon combined with thymopeptide alpha1 was used to treat the immune-tolerance HBV carriers, and the effect was evaluated by measuring the liver function, HBV markers, HBVDNA quantifying assessment, T cells and so on. Our investigations display that the aminotransferase of the therapy group and control group both increase and the rising ratios are 51% and 26%, respectively, which has significant differences (P<0.05,χ~2 -test). The result indicates the immune tolerance can be broke after curing and the effect of the therapy group is better than the control group. Furthermore, the HBeAg seroconversion of the two groups (therapy/control) at the end of treatments and the 6...